Azra Kurbasic
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Polygenic prediction of body mass index and obesity through the life course and across ancestries.
Journal: Nature medicine
Published: October 31, 2024
Author Correction: The power of genetic diversity in genome-wide association studies of lipids.
Journal: Nature
Published: May 26, 2023
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
Journal: JAMA dermatology
Published: April 19, 2023
Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3).
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: May 23, 2022
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.
Journal: Dermatology and therapy
Published: May 07, 2022
A saturated map of common genetic variants associated with human height.
Journal: Nature
Published: December 19, 2021
A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids.
Journal: American journal of human genetics
Published: December 02, 2021
Exposome-wide ranking of modifiable risk factors for cardiometabolic disease traits.
Journal: Scientific reports
Published: March 25, 2021
Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study.
Journal: Cell reports. Medicine
Published: December 08, 2020
Correction to: The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study.
Journal: Diabetologia
Published: November 13, 2020
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Journal: The British journal of dermatology
Published: September 25, 2020
Last Updated: 09/26/2026